ArticlePakistan journal of medical sciences2026
A comparative analysis of cardiac bridging Integrator 1 (cBIN1) levels in patients with heart failure and healthy controls: A prospective case-control study.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare cardiac bridging integrator 1 (cBIN1) levels between healthy individuals and patients with heart failure (HF), and to assess changes in cBIN1 levels following therapeutic intervention to evaluate its potential as a diagnostic and prognostic biomarker. Methodology: A case-control study with three months follow-up was conducted in the Department of Physiology, Baqai University Hospital, Karachi, Pakistan, from June 2024 to November 2024. A total of 200 adults aged 40-70 years were recruited, comprising 50 healthy controls with left ventricular ejection fraction (LVEF ≥60%) and 150 patients with heart failure (HF): Heart failure with reduced, moderatly reduced and preserved ejection fraction, HFrEF (LVEF ≤40%), HFmrEF (LVEF 40-49%) and HFpEF (LVEF ≥50%). Enzyme linked immuno-essay (ELISA) was used to measure the plasma cBIN1 level at baseline. For the statistical analysis, ANOVA and t-tests, as well as post-hoc testing with significance at p<0.05, were used. Results: Mean plasma cBIN1 was 9.221±0.440 ng/mL in healthy controls, 1.193±0.059 in HFpEF, 1.009±0.063 in HFmrEF and 0.799±0.050 in HFrEF (p<0.001), with the lowest levels in HFrEF on post-hoc testing (p<0.001 for all comparisons against controls). Levels were significantly lower in participants with higher BMI (3.19±3.65 vs 0.99±0.20; t=2.084, p=0.038) and did not differ significantly by gender (p>0.05). No significant change was observed after three months of follow-up (p=0.963). Conclusion: Plasma cBIN1 levels were significantly lower in patients with heart failure than in healthy controls, with the lowest levels observed in HFrEF. These findings suggest that cBIN1 may have value in stratifying HF severity and warrant evaluation in larger, multicenter cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.